Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$3.20	$3.09	$1.50 ▼ $3.87	$23.38M	0.83	7,182 shs	N/A
HYPD Hyperion DeFi	$6.69 -5.0%	$8.98	$0.85 ▼ $75.18	$39.44M	2.42	767,143 shs	382,832 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
RNXT RenovoRx	$1.24 +1.6%	$1.29	$0.75 ▼ $1.69	$44.62M	1.26	125,021 shs	339,531 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	0.00%	+0.31%	-14.44%	+64.95%	-17.31%
HYPD Hyperion DeFi	-4.97%	+21.64%	-48.10%	+492.04%	-89.05%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RNXT RenovoRx	+1.64%	+3.33%	-6.06%	+5.08%	+10.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	0.3596 of 5 stars	1.0	0.0	0.0	0.0	2.4	0.8	0.6
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	3.353 of 5 stars	3.5	5.0	0.0	0.0	3.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
HYPD Hyperion DeFi	2.00	Hold	$2.00	-70.10% Downside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
RNXT RenovoRx	3.00	Buy	$7.25	484.68% Upside

Current Analyst Ratings Breakdown

Latest PHXM, HYPD, RNXT, and EGRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EGRX Eagle Pharmaceuticals	$257.55M	0.16	$8.00 per share	0.40	N/A	∞
HYPD Hyperion DeFi	$60K	624.40	N/A	N/A	($695.52) per share	-0.01
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
RNXT RenovoRx	$40K	1,133.67	N/A	N/A	$0.19 per share	6.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-369.98%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	N/A

Latest PHXM, HYPD, RNXT, and EGRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.25 million	$0.42 million
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	0.34	0.34
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
RNXT RenovoRx	N/A	9.07	9.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EGRX Eagle Pharmaceuticals	85.36%
HYPD Hyperion DeFi	25.84%
PHXM PHAXIAM Therapeutics	0.40%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
EGRX Eagle Pharmaceuticals	28.90%
HYPD Hyperion DeFi	10.86%
PHXM PHAXIAM Therapeutics	1.94%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable

PHXM, HYPD, RNXT, and EGRX Headlines

Recent News About These Companies

RenovoRx Revenue Jumps 28 Percent in Q2

August 14 at 11:55 PM | theglobeandmail.com

RenovoRx Reports Strong Q2 2025 Revenue Growth

August 14 at 11:55 PM | msn.com

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates

August 14 at 6:21 PM | zacks.com

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

August 14 at 4:19 PM | businesswire.com

RenovoRx (RNXT) Projected to Post Earnings on Thursday

August 12 at 2:33 AM | americanbankingnews.com

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

August 6, 2025 | globenewswire.com

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025 | finance.yahoo.com

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

July 14, 2025 | businesswire.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

Le BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisions

May 15, 2025 | fr.investing.com

Transcription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentes

May 15, 2025 | fr.investing.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025 | businesswire.com

Earnings Preview For RenovoRx

May 14, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM, HYPD, RNXT, and EGRX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

$3.20 0.00 (0.00%)

As of 08/13/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Hyperion DeFi NASDAQ:HYPD

$6.69 -0.35 (-4.97%)

As of 08/14/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/12/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

RenovoRx NASDAQ:RNXT

$1.24 +0.02 (+1.64%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.14 -0.10 (-8.39%)

As of 04:43 AM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time